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expression of T cell activation markers on peripheral blood 
mononuclear cells. The population of XAGE-1b-specific T 
cells comprised both CD4+ and CD8+ T cells secreting 
both type I and II cytokines. Epitope mapping showed that 
T cells predominantly targeted the N-terminal part of the 
XAGE-1b protein, while the B cell response was directed 
against the C-terminal domain. Our study for the first time 
provides evidence for the presence of XAGE-1b-specific 
T cells within adenocarcinoma tissue, which supports the 
concept that XAGE-1b acts as a genuine tumor antigen 
and, therefore, might form an attractive target for a vac-
cine-based approach of immunotherapy.
Keywords XAGE-1b · CT antigen · Adenocarcinoma · 
Lung cancer
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B-LCL  EBV transformed B cell lines
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Abstract XAGE-1b is a cancer/testis antigen aber-
rantly expressed in pulmonary adenocarcinoma. Systemic 
antibody and T cell responses have been demonstrated in 
adenocarcinoma patients, but so far, local antigen-specific 
immunity has not been reported. In this study, XAGE-1b 
expression by tumor cells as well as the presence of sys-
temic and/or local XAGE-1b-specific immunity was 
assessed in peripheral blood, tumor tissue and tumor-
draining lymph nodes of Caucasian patients with pulmo-
nary adenocarcinoma. XAGE-1b protein expression was 
detected in 43.6 % (17 of 39) of patients when at least two 
different parts of a resected tumor were assessed. In 20 
patients, analysis of T cells isolated and expanded from the 
primary tumor and its draining lymph node demonstrated 
XAGE-1b-specific responses in two patients. XAGE-
1b-specific immunoglobulin G antibodies were found in 
3 of 40 patients. These three antibody-positive patients 
had also mounted a systemic T cell response to XAGE-
1b, measured by proliferation, cytokine production and 
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TKI  Tyrosine kinase inhibitors
TILs  Tumor-infiltrating lymphocytes
Introduction
Lung cancer is the most common cause of cancer mortal-
ity in men in the developed world and one of the leading 
causes in women [1]. Non-small cell lung cancer (NSCLC) 
comprises about 80 % of all lung cancers [2]. The 5-year 
survival rates rapidly drops with increased stage at diagno-
sis [3]. The current treatment modalities include surgery, 
radiotherapy combined with chemotherapy or palliative 
chemotherapy [4]. Active immunotherapy, focusing on the 
reinforcement of the tumor-specific T cell response, has 
emerged as a new modality to treat cancer [5]. NSCLC is 
characterized by infiltration of different types of immune 
cells. Infiltration with M1 macrophages and T cells is posi-
tively associated with clinical outcomes, suggesting a pro-
tective role for the immune system in NSCLC [6]. This is 
supported by the recent finding that infusion of antibodies 
blocking programmed cell death protein 1 (PD1) on T cells 
has clinical impact in advanced NSCLC [7]. Peptide-based 
therapeutic vaccines aim at the induction of tumor-specific 
T cell responses [5]. This approach is highly dependent on 
the identification of suitable tumor antigens [8]. An impor-
tant group of tumor antigens is encoded by the cancer/
testis (CT) genes. These CT antigens are present in a sig-
nificant subset of tumors, including NSCLC [9], and com-
prise XAGE-1. The XAGE-1 protein has four transcripts 
(a, b, c and d), of which XAGE-1b (81 amino acids) is the 
mainly expressed isoform [10, 11]. Nuclear staining has 
been observed in 53 % of pulmonary adenocarcinomas, a 
subtype that accounts for 40 % of NSCLC, but not in adja-
cent normal tissues indicating its preferential expression 
by cancer cells [12]. A positive association between the 
expression of XAGE-1b and HLA class I with prolonged 
survival was reported [10], although no link with XAGE-
1b-specific immunity was made. A recent study revealed 
the presence of XAGE-1b-specific antibodies in 10 % of 
all NSCLC patients and in 19 % of stage IIIb/IV adeno-
carcinoma patients. More than half of the patients with a 
XAGE-1b antibody response displayed a concomitant sys-
temic CD4+ and CD8+ T cell response [13].
To date, studies on XAGE-1b have been performed in 
Asian populations but not in Caucasian subjects. Further-
more, no data exist on the presence of XAGE-1b-specific 
T cells within the tumor or its draining lymph node. To 
this end, we have conducted an explorative study in which 
a European cohort of patients with pulmonary adenocar-
cinoma was studied with respect to XAGE-1b expression 
and the presence of systemic and local XAGE-1b-mediated 
immunity.
Materials and methods
Patients and tissue collection
Forty patients with histologically proven primary NSCLC, 
subtype adenocarcinoma, were included from 2011 to 
2014. Patients either underwent surgical resection (stage 
I/II), stereotactic radiotherapy (stage I), combined chemo-
radiotherapy (stage III) or chemotherapy alone (stage IV). 
Stage IV patients with epidermal growth factor receptor 
(EGFR) mutations were treated with tyrosine kinase inhibi-
tors. The available tissue blocks of formalin-fixed paraffin 
embedded tumor were collected. Peripheral blood mononu-
clear cells (PBMCs) were isolated by Ficoll density centrif-
ugation and subsequently cryopreserved in liquid nitrogen 
[14, 15]. In case of surgical resection, fresh tissue from the 
primary tumor and its draining lymph node were obtained.
XAGE‑1b immunohistochemistry (IHC)
Tumor blocks were cut in 4-µm sections and deparaffinized 
in xylene. Endogenous peroxidase activity was blocked 
by incubation in 0.3 % hydrogen peroxide/methanol for 
10 min at room temperature (RT). Antigen retrieval was 
performed by heating the samples to 97 °C for 30 min in 
citrate buffer (pH 6.0, DAKO, Glostrup, Denmark), cooled 
on ice and incubated at RT for 1 h with 2 µg/ml XAGE-1 
mouse monoclonal antibody LX199#5 (kindly provided 
by the Ludwig Institute for Cancer Research, LICR) in 
phosphate-buffered saline (PBS, Fresenius Kabi Bad Hom-
burg, Germany) with 1 % bovine serum albumin (BSA). 
After washing, the slides were incubated with horseradish 
peroxidase-conjugated anti-mouse IgG (DAKO envision) 
for 30 min at RT. NovaRed (Vector, Burlingame, USA) was 
applied as a chromagen, and sections were counterstained 
with Mayer’s hematoxylin (Klinipath). All slides were 
mounted with Pertex mounting medium (HistoLab, Swe-
den). All washing steps were done with PBS.
XAGE-1b expression was scored according to a previ-
ously described method [11] as negative (<5 % cancer cells 
positive), focal (5–10 % positive), intermediate (11–50 % 
positive) or diffuse (>50 % positive). From each slide, 10 
random tumor fields (magnification 20×, approximately 
the size of a biopsy) were scored for XAGE-1b expression. 
When available, tissue blocks from multiple tumor sections 
were assessed.
XAGE‑1b protein and overlapping peptides
E. coli-produced recombinant XAGE-1b protein (81 amino 
acids) was obtained using a XAGE-1 plasmid DNA, kindly 
provided by the LICR. Five synthetic overlapping peptides 
covering the entire sequence of the XAGE-1b protein were 
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synthesized at the LUMC by solid-phase strategies on an 
automated peptide synthesizer (Abimed AMS 422, Ger-
many) using Fmoc chemistry. Peptides were analyzed by 
reverse-phase HPLC, dissolved in DMSO at 50 mg/ml, 
aliquoted and stored at −80 °C until use. The amino acid 
sequences of the five peptides are:
p1, amino acid 1-32, MESPKKKNQQLKVGILHLGS 
RQKKIRIQLRSQ;
p2 amino acid 18-42, LGSRQKKIRIQL-RSQCATW 
KVICKS;
p3, amino acid 34-59, ATWKVICKSCISQTPGINLDL 
GSGVK;
p4, amino acid 37-68, KVICKSCISQTPGINLDLGSGV 
KVKIIPKEEH;
p5, amino acid 55-81, GSGVKVKIIPKEEHCKMPE-A 
GEEQPQV.
Working solutions were prepared at a concentration of 
2.5 mg/ml and stored at −20 °C.
Detection of XAGE‑1b‑specific IgG antibodies
Serum samples were analyzed for XAGE-1b peptide-
specific immunoglobulin G (IgG) by ELISA. Serum sam-
ples with known high IgG titers for XAGE-1b (KLU 187, 
kindly provided by Dr. E. Nakayama, Okayama University, 
Japan) were used to develop the ELISA. One serum sample 
(X-14) with proven high XAGE-1b IgG titers was included 
in each experiment as a positive control. All washing steps 
were done with PBS. A 96-well EIA/RIA plate (Costar 
3590) was coated overnight at 4 °C with 50 μl of the indi-
vidual XAGE-1b peptides and a mix of all peptides (5 μg/
ml of each peptide diluted in 0.1 M carbonate/bicarbonate 
coating buffer; Merck, Darmstadt, Germany). The next day, 
non-specific binding sites of the plate were blocked with 
5 % FCS/PBS (100 μl/well, fetal calf serum, PAA labora-
tories, Austria) for 1 h at RT. Subsequently, serially diluted 
serum samples (1:100, 1:500, 1:1000, 1:2000, 1:4000 in 
blocking buffer) were added in triplicate wells (50 μl/well) 
and incubated at RT for 2 h. Next, goat antihuman IgG-
horseradish peroxidase (HRP, Southern Biotechnology, 
Birmingham, AL) was added (diluted 1:3000 in blocking 
buffer) and incubated for 1 h at RT. Finally, tetramethylb-
enzidine liquid substrate (Sigma Aldrich, 50 μl/well) was 
added for the colorimetric enzymatic reaction, which was 
stopped by adding 50 μl/well of 2 M H2SO4 (Merck), and 
the plate was read in an ELISA reader at 450 nm. The aver-
age OD value of the triplicate uncoated wells (background 
value) was calculated and an outlier per triplicate was dis-
carded when the value exceeded the average plus 2× stand-
ard deviation (SD). A positive XAGE-1b peptide-specific 
IgG response was defined as an average of the triplicate 
wells which was at least twofold above background value.
Cell culture
The tumor-infiltrating lymphocytes (TILs) culture method 
has been published previously [14, 15]. Briefly, TILs were 
isolated by mincing fresh tumor tissue into pieces followed 
by a 2- to 3-week homeostatic in vitro culture in Iscove’s 
modified Dulbecco’s medium (IMDM) supplemented with 
10 % human AB (hAB) serum (PAA laboratories) and a 
mix of homeostatic cytokines: 10 % T cell growth factor 
(TCGF, Zeptometrix, USA), 5 ng/ml of interleukin-15 (IL-
15; Peprotech) and (only on day 1) 5 ng/ml of IL-7 (Pepro-
tech). Lymph node (LN) mononuclear cells were isolated 
from tumor-draining lymph nodes and cultured for a week 
in medium alone (LN neg) or supplemented with a mix 
of 5 XAGE-1b overlapping peptides (LN XAGE, 2.5 µg/
ml/peptide), after which the T cells were expanded with 
recombinant human IL-2 (150 IU/ml, refreshed 3 times 
per week) for 2–3 weeks. After harvesting, the T cells 
were evaluated for presence of XAGE-1b-specific CD4+ 
CD25+ Foxp3high T cells, XAGE-1b-specific proliferation 
and cytokine production.
Detection of XAGE‑1b‑specific CD4CD25+ Foxp3high  
T cells
PBMCs, TILs and LN cells were stained for CD4, CD8, 
Foxp3 and CD25 as previously reported [16, 17].
Analysis of XAGE‑1b‑specific T cells by proliferation 
assay and cytokine profile
T cells (50,000/well) were stimulated with autologous 
monocytes pulsed with XAGE-1b peptides and/or protein 
(5 μg/ml) in triplicate wells in a three-day proliferation 
assay [14] with phytohaemagglutinin (PHA) (Remel, Ger-
many) used as positive control. Supernatants collected after 
2 days were analyzed for Th1/Th2 cytokines (IFNγ, TNF-
α, IL-10, IL-5, IL-4, IL-2) by cytometric bead array (CBA, 
BD Biosciences). Proliferation was measured by 3H-thy-
midine incorporation (0.5 μCi/well) during the last 18 h of 
the assay [18]. The stimulation index (SI) was calculated 
by taking mean counts of stimulated wells divided by mean 
counts of the medium control wells. A XAGE-1b-specific T 
cell response was defined by either a SI index of >3 or by 
XAGE-1b-specific cytokine production, which was defined 
as a cytokine concentration above the cutoff value (20 pg/
ml, except for IFNγ for which the cutoff was 100 pg/ml) 
and more than twice the concentration of medium control 
[19].
1112 Cancer Immunol Immunother (2015) 64:1109–1121
1 3
ELISPOT
Details of the four-day IFNγ ELISPOT assay have been 
reported previously [17]. Spots were counted with a fully 
automated computer-assisted video imaging analysis sys-
tem (BioSys 5000). Specific spots were calculated by 
subtracting the mean number of spots in quadruplicate 
wells + 2 × SD of the medium only control from the mean 
number of spots in test wells. Antigen-specific T cell fre-
quencies were considered to be increased compared to 
medium control when specific T cell frequencies were 
≥1/10,000 [17].
Analysis of XAGE‑1b‑specific T cells 
by multiparameter flow cytometry
T cells were stimulated overnight with autologous mono-
cytes pulsed with individual XAGE-1b peptides (5 μg/
ml), a XAGE-1b peptide mix (5 μg/peptide/ml) and 
XAGE-1b protein (10 μg/ml). E7 protein of the human 
papillomavirus type 16 (HPV16 E7) was used as nega-
tive control. The percentage and polarization of XAGE-
1b-specific T cells was measured by simultaneous stain-
ing for T cell markers (CD3, CD4 and CD8), T cell 
activation markers (CD137 and CD154) and cytokines 
(IFNγ, IL-2) according to standard operating proce-
dures (SOPs) [14, 16, 20]. XAGE-1b-specific T cells 
were detected when the percentage of XAGE-1b-specific 
CD4+ CD154+ CD137+, CD8+ CD137+ or cytokine-
producing T cells was at least twice the percentage 
detected in the medium control. The responding cells 
were visible as a clearly distinguishable population in 
the flow cytometry contour plot. An example of a gating 
strategy is provided in Supplementary Figure 1.
Isolation of XAGE‑1b‑specific T cell clones
T cell clones were isolated from PBMCs using limit-
ing dilution as described earlier [15]. Specificity of T cell 
clones for XAGE-1b was tested by proliferation assay on 
peptide or protein-loaded irradiated autologous Epstein–
Barr virus (EBV)-transformed B cell lines (B-LCL) or 
autologous monocytes. Furthermore, clones were tested by 
flow cytometry for phenotype (CD4/CD8) and T cell recep-
tor Vβ (TCRVβ) expression using a TCRVβ kit (Beckman 
Coulter) comprising eight sets of antibodies, each consist-
ing of three differently labeled antibodies specific for three 
different TCRVβ families, ultimately covering about 70 % 
of the normal human TCRVβ repertoire. A TCRVβ was 
considered dominant (>10 %), subdominant (3–10 %) or 
minor (<3 %) based on the percentage of T cells using the 
same TCRVβ [14, 21].
Results
An overview of patient characteristics is presented in 
Table 1. The mean age was 65.9 years (range 45–82 years), 
and the male/female ratio was 20/20.
XAGE‑1b expression in lung adenocarcinoma
In our patient cohort, the whole primary tumor was avail-
able for XAGE-1b staining from 28 patients who under-
went surgical resection (stage I/II). A biopsy of the primary 
tumor was available in nine cases (two stage I/II patients 
and seven stage III/IV patients). In three cases, XAGE-1b 
expression was assessed on metastasized tissue only. In one 
patient (X-4), the biopsy of the primary tumor could not 
be retrieved, and hence, XAGE-1b status was not assessed. 
Overall, in 17 of 39 evaluable cases (43.6 %), XAGE-1b 
expression was observed: focal (n = 5), intermediate (n = 6) 
and diffuse (n = 6). Positive staining was found in the pri-
mary tumor (n = 15), metastatic tissue (n = 1) or both 
(n = 1) (Table 1). The XAGE-1b staining pattern was always 
nuclear, and occasionally, also cytoplasmic staining was 
observed. An example of XAGE-1b staining is presented 
in Supplementary Figure 2. While 54 % (15 of 28) of the 
resected tumor specimens stained positive for XAGE-1b, this 
was only the case for one out of eight biopsies evaluated. To 
assess whether the XAGE-1b status in biopsies truly reflects 
the XAGE-1b status of the primary tumor, 10 random tumor 
fields of the resected tumor specimens (n = 28; magnifica-
tion 20×, approximately the size of a biopsy) were scored 
for XAGE-1b overexpression. While none of the 13 previ-
ously scored negative tumors showed XAGE-1b staining 
in the 10 random fields, the 15 XAGE-1b-positive resected 
tumors displayed XAGE-1b staining in (on average) 5.2 out 
of 10 fields (range 2–10). In addition, multiple tissue blocks 
of the same tumor (average 3.0 blocks, range 2–6) were stud-
ied for 22 of 28 operated patients. In 17 of 22 cases, staining 
score (positive or negative) was identical in all blocks from 
the same case (Table 1). Our data demonstrate that XAGE-
1b overexpression is found in about 40 % of all tumors; how-
ever, positive tumors do not show overexpression in all ran-
domly selected tumor fields.
XAGE‑1b‑specific T cells are present in the primary 
lung tumor and its draining lymph nodes
Fresh samples of tumor and lymph node tissue were col-
lected from 24 of the 28 stage I/II adenocarcinoma patients. 
In 20 cases, we successfully expanded TILs. Tumor-drain-
ing lymph node (LN) mononuclear cells were expanded in 
vitro in the presence (LN XAGE) or absence (LN neg) of 
exogenous XAGE-1b peptides. The phenotype (CD4, CD8, 
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Table 1  Overview of patient characteristics, XAGE-1b immunohistochemistry and IgG response
1 CT chemotherapy, CT-RT combined chemo-radiotherapy, RT radiotherapy, TKI tyrosine kinase inhibitors
2 XAGE-1b immunohistochemistry (IHC) scored as negative (<5 % positive), focal (5–10 %), intermediate (11–50 %) and diffuse (>50 %). NT 
not tested
3 10 random tumor fields (magnification 20×) from each slide were scored. The number (Nr.) of positively scored fields are given. NT not tested
4 When available, XAGE-1b overexpression was assessed in multiple tumor sections
5 XAGE-1b-specific IgG antibody response is shown
ID Stage Treatment1 Tumor material XAGE-1b IHC2 Number of + fields3 Number of + sections4 Metastasis XAGE-1b IgG5
X-1 I RT Biopsy Negative –
X-2 IV CT Biopsy Negative –
X-3 IIIa CT-RT Biopsy Negative –
X-4 IIIb CT Biopsy +
X-5 I/II Surgery Resection Focal 2 1 of 3 –
X-6 IV CT Biopsy Negative –
X-7 I/II Surgery Resection Focal 4 1 of 1 –
X-8 IIIa CT-RT Biopsy Negative –
X-9 I/II Surgery Resection Intermediate 10 1 of 1 –
X-10 IIIb CT-RT Biopsy Negative –
X-11 IV CT Metastasis Negative –
X-12 I/II Deceased Biopsy Focal –
X-13 I/II Surgery Resection Negative 0 –
X-14 I/II Surgery Resection Diffuse 10 2 of 3 Diffuse +
X-15 I/II Surgery Resection Focal 4 1 of 1 –
X-16 IIIa CT-RT Metastasis Negative –
X-17 I/II Surgery Resection/Metastasis Diffuse 6 2 of 2 Negative –
X-18 I/II Surgery Resection/Metastasis Negative 0 0 of 2 Negative –
X-19 I/II Surgery Resection Focal 3 1 of 3 –
X-20 I/II Surgery Resection Negative 0 0 of 3 –
X-21 I/II Surgery Resection Intermediate 4 2 of 2 –
X-22 I/II Surgery Resection Intermediate 3 2 of 2 –
X-23 I/II Surgery Resection Negative 0 0 of 2 –
X-24 I/II Surgery Resection Intermediate 6 2 of 2 –
X-25 I/II Surgery Resection Negative 0 0 of 2 –
X-26 I/II Surgery Resection Intermediate 4 1 of 2
X-27 I/II Surgery Resection Negative 0 0 of 6 +
X-28 I/II Surgery Resection Negative 0 0 of 4 –
X-29 I/II Surgery Resection Negative 0 0 of 2 –
X-30 I/II Surgery Resection Intermediate 3 1 of 3 –
X-31 I/II Surgery Resection Negative 0 0 of 1 –
X-32 I/II Surgery Resection Negative 0 0 of 3 –
X-33 I/II Surgery Resection Negative 0 0 of 5 –
X-34 IV TKI Metastasis Diffuse –
X-35 I/II Surgery Resection Diffuse 6 1 of 1 –
X-36 I/II Surgery Resection Diffuse 7 4 of 4 –
X-37 I/II Surgery Resection Diffuse 6 3 of 3 –
X-38 I/II Surgery/CT Resection/Metastasis Negative 0 0 of 2 Negative –
X-39 IV CT Biopsy Negative –
X-40 I/II Surgery Resection Negative 0 0 of 4 –
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Foxp3) and activation status (i.e., CD25 expression) of 
these T cells are presented in Supplementary Figure 3.
Next, the presence of local (TILs/LN neg/LN XAGE) as 
well as circulating XAGE-1b-specific T cells (PBMCs) was 
investigated by analysis of XAGE-1b-specific proliferation 
and cytokine secretion in these 20 patients. In one patient 
(X-14) with diffuse (>50 %) XAGE-1b staining in the pri-
mary tumor, a T helper 1 (Th1) response to XAGE-1b was 
detected (Fig. 1). XAGE-1b-specific secretion of IFNγ and 
TNFα was detected in both TILs and LN XAGE cells after 
co-culture with autologous monocytes pulsed with a mix of 
XAGE-1b overlapping peptides. In addition, the T helper 
type 2 (Th2) cytokines IL-5 and IL-10 were secreted (Sup-
plementary Figure 4). Despite the XAGE-1b-specific high 
production of cytokines, the proliferative response was low 
in TILs (SI index 0.7) and LN XAGE (SI 2.1), indicating 
that these T cells had poor proliferative capacity after their 
initial expansion (data not shown).
Another patient (X-20), without XAGE-1b expres-
sion in the primary tumor, showed XAGE-1b-specific T 
cell reactivity in its draining LN. XAGE-1b-specific IFNγ 
and TNFα production was detected in the LN cells only 
expanded with IL-2 (LN neg) (Fig. 1), and these T cells 
also produced IL-5 but not IL-10 (Supplementary Fig-
ure 4). A XAGE-1b-specific response in the LN cells cul-
tured with XAGE-1b peptides (LN XAGE) was not dem-
onstrated potentially due to the high background cytokine 
production in these activated T cells after culture (Fig. 1). 
Again, despite high cytokine release in the LN neg cells, 
the XAGE-1b-specific proliferative response was low (SI 
1.2, data not shown).
Overall, we found local XAGE-1b-mediated Th1/Th2 
cell immunity in two of 20 patients tested indicating that 
XAGE-1b acts as a genuine tumor antigen.
Identification of XAGE‑1b B cell epitopes
The ELISA for measuring XAGE-1b-specific IgG anti-
bodies was developed with a high IgG titer serum sample 
(KLU 187) [13] as positive control. A relatively strong 
Fig. 1  Local XAGE-1b-medi-
ated immunity, Th1 response. 
Day 2 supernatants from 
PBMCs, TILs and LN cells, co-
cultured with XAGE-1b pulsed 
monocytes, were analyzed for 
Th1 (IFNγ and TNF-α) and Th 
2 (IL-5 and IL-10) cytokine 
release. A positive response 
(indicated with asterisks) was 
defined by a cytokine concen-
tration above the cutoff value 
(20 pg/ml, except for IFNγ, 
100 pg/ml) and more than twice 
the concentration of medium 
control. Depicted here are the 
Th1 cytokines. XAGE-1b-spe-
cific Th1 cytokine release was 
observed in TILs (X-14) and 
LN cells (X-14, X-20). Included 
are the results from one negative 
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XAGE-1b-specific IgG response was detected in patient 
X-14 (Fig. 2). In total, 3 out of 40 evaluated patients 
(7.5 %) displayed a XAGE-1b-specific IgG response when 
tested against a mix of the 5 XAGE-1b overlapping pep-
tides. These three serum samples were also tested against 
the individual XAGE-1b peptides (Fig. 2c). Although pep-
tide p5 showed the strongest response, the sera showed a 
response to multiple epitopes in XAGE-1b.
Of these three patients, one patient (X-14) expressed 
XAGE-1b in the tumor and mounted a local XAGE-
1b-specific T cell response. Surprisingly, the second patient 
(X-27) did not show XAGE-1b expression in the tumor, 
despite the analysis of six separate tumor sections. For the 
last patient (X-4), the XAGE-1b tumor status could not be 
assessed due to unavailability of the tumor sample.
XAGE‑1b‑specific T cells are present in peripheral 
blood both direct ex vivo and after in vitro expansion
Since the presence of IgG antibodies indicate an underlying 
T cell response [13], the three patients (X-4, X-14, X-27) 
with XAGE-1b-specific IgG were analyzed for circulating 
XAGE-1b-specific T cells. First, PBMCs were stimulated 
with the pool of XAGE-1b peptides or medium only and 
examined in a direct ex vivo IFNγ ELISPOT. In one patient 
(X-4), a strong XAGE-1b-specific IFNγ response was dem-
onstrated (Supplementary Figure 5) indicative for the pres-
ence of circulating XAGE-1b-specific T cells. PBMCs of 
the other patients (X-14, X-27) did not show a direct ex 
vivo XAGE-1b-specific T cell response (data not shown).
Subsequently, PBMC samples of these three patients 
were stimulated with the mix of XAGE-1b-overlapping 
peptides in vitro for 10 days and then tested for XAGE-
1b-specific proliferation and Th1/Th2 cytokine production 
(Fig. 3). Patient X-4 showed a Th1 response to XAGE-1b 
reflected by the production of high amounts of IFNγ and 
low levels of IL-5 and IL-10 to peptide p2 and to the mix 
of five peptides. Similar to our previous observation, the 
proliferative response of the T cells was modest at best to 
the peptide mix (SI 2.5) and undetectable to individual pep-
tides. The PBMC culture of patient X-14 produced large 
amounts of IFNγ when stimulated with peptide p1, p2 or 
the peptide mix as well as low amounts of TNFα and IL-5 













































































































Fig. 2  XAGE-1b-specific IgG antibodies in patient sera. a Example 
of a XAGE-1b-specific IgG response (X-14) to XAGE-1b peptide 
mix. KLU 187 represents a serum sample previously shown to have 
high IgG antibody titers [13] and was used as positive control to set 
up the ELISA. Serial dilutions are shown. b Example of a patient 
(X-18) with no XAGE-1b IgG response to XAGE-1b peptide mix. 
X-14 was used as positive control. c IgG response (serum 1:100 
diluted) to individual XAGE-1b peptides in 3 of the 40 tested patients 
shows broad recognition. A positive response was defined as at least 
a twofold increase compared to background (no antigen) and is indi-
cated with asterisks
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of this patient proliferated when stimulated with p1 (SI 8.5) 
and peptide mix (SI 8.4) but not when stimulated with p2.
The third patient (X-27) neither showed cytokine pro-
duction nor a proliferative response specific for XAGE-1b 
(Fig. 3). However, we observed an unusually high concen-
tration of CD14+ myeloid cells in the peripheral blood of 
this patient. Myeloid-derived suppressor cells have been 
shown to be elevated and to have a suppressive effect on T 
cells in NSCLC [22, 23]. Therefore, the CD14+ cells were 
removed from the PBMCs by magnetic-activated cell sort-
ing (MACS), and the remaining cells were stimulated with 
the XAGE-1b peptide mix. As a result, the 10-day cultured 
PBMCs produced IFNγ, TNFα and IL-5 and proliferated 
upon stimulation with p2 (SI 3.9) and the XAGE-1b pep-
tide mix (SI 4.1) (Supplementary Figure 6). Thus, XAGE-
1b-specific T cells are present in the peripheral blood of 
XAGE-1b IgG-positive patients, but their reactivity can be 
obscured by a CD14+ myeloid population.
Type and specificity of the XAGE‑1b‑specific T cell 
response
To type and enumerate XAGE-1b-specific T cells in 8-week 
cultured PBMCs, we assessed the frequency of CD4+ and 
CD8+ T cells with increased expression of the T cell acti-
vation markers CD137 and CD154 after stimulation with 
ne










































































































































































Fig. 3  Circulating XAGE-1b-specific T cells: proliferation and 
release of type I/II cytokines. a PBMC samples from three patients 
(X-4, X-14, X-27) with XAGE-1b-specific IgG antibodies were 
stimulated with XAGE-1b overlapping peptides in a 10-day culture 
and subsequently tested for XAGE-1b-specific proliferation. A posi-
tive response (indicated with asterisk) was defined as a SI index of 
≥3. Patient X-14 showed a response specific for peptide p1 and 
XAGE-1b peptide mix, X-4 showed a modest proliferative response 
to the XAGE-1b peptide mix, whereas X-27 showed no prolifera-
tive response at all. b Release of Th1 cytokines (IFNγ, TNFα) was 
observed in two patients (X-4, X14) specific for peptide p1, p2 and 
peptide mix. c Release of Th2 cytokines (IL-10, IL-5) was observed 
in two patients (X-4, X14) and was specific for peptide p1, p2 and 
peptide mix. The third patient (X-27) showed no detectable response 
(b, c)
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antigen-pulsed autologous monocytes (Fig. 4a). CD4+ T 
cells of patient X-4 showed a strong response toward stim-
ulation with p1, p2 and the peptide mix. A weak response 
was observed to p3, p4 and XAGE-1b protein. The type 
I cytokines IFNγ and/or IL-2 were produced by the dou-
































































































































































Fig. 4  Type and specificity of XAGE-1b-specific CD4 T cell 
response. a The CD4+ T cells in the 8-week cultured PBMCs of 
patient X-14 were gated (see Supplementary Figure 1). Subsequently, 
CD4+ double-positive (CD137+ CD154+) T cells were gated. 
Finally, the intracellular IFNγ/IL-2 production within this popula-
tion was plotted. Upon stimulation with XAGE-1b peptide mix and 
XAGE-1b, a specific upregulation of the T cell activation markers 
CD137/CD154 and the intracellular expression of IFNγ and IL-2 are 
demonstrated as compared to medium control and the negative control 
protein (HPV16 E7). b The specificity of CD4+ CD137+ CD154+ 
T cells for individual peptides and XAGE-1b protein and type I intra-
cellular cytokine profile are shown for two patients (X-4 and X-14). 
Asterisks indicate positive responses (at least twice the percentage 
detected in the medium control). For patient X-4, a CD4+ T cell 
response was observed specific for peptide p1, p2 and the peptide mix, 
as well as a weak response to p3, p4 and p5. Patient X-14 displayed a 
strong CD4+ T cell response when stimulated with p1, peptide mix 
and XAGE-1b protein as well as a moderate response to p2
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stimulation with p1, p2, p3, p4 and the peptide mix. Unfor-
tunately, the number of expanded CD8+ T cells in this cul-
ture was too low to thoroughly assess XAGE-1b-specific 
CD8+ T cell reactivity.
The cultured PBMCs of patient X-14 showed a strong 
CD4+ T cell mediated response when stimulated with p1, 
peptide mix and XAGE-1b protein as well as a moderate 
response to p2, corroborating the earlier data (Fig. 4b). The 
cytokine profile of double-positive T cells mainly showed 
high IFNγ production specific for p1 and the peptide mix. 
Notably, the CD8+ T cells within this culture reacted to p1, 
the peptide mix and XAGE-1b protein (Supplementary Fig-
ure 7). Surprisingly, the peptide- and protein-specific IFNγ 
production in these CD8 T cells is not accompanied by an 
increased expression of the activation marker CD137 (Sup-
plementary Figure 8).
Subsequently, T cell clones were isolated from the bulk-
cultured PBMCs from patients X-4 and X-14. During the 
cloning procedure, the expanded PBMCs were kept in cul-
ture, and subsequently, the established clones and bulk-cul-
tured PBMCs were characterized with respect to TCR-Vβ 
usage and antigen-specific proliferation. Analysis of TCR-Vβ 
usage showed the presence of at least 11 different TCR-Vβ 
families of CD4+ T cells in the bulk-cultured PBMCs of X-4 
(Supplementary Figure 9A). Upon stimulation with peptide 
p1, p2, the peptide mix and XAGE-1b protein, the bulk-cul-
tured PBMCs of this patient showed a proliferative response 
(Supplementary Figure 9B). Only one XAGE-1b-specific 
CD4+ T cell clone could be established (Supplementary 
Figure 9C). This clone (X-4.6) responded to p1, p2 and the 
peptide mix. The TCR-Vβ analysis did not lead to the identi-
fication of a specific TCR-Vβ family usage (data not shown), 
indicating that the TCR-Vβ used was outside the range of 
families covered by the eight sets of antibodies.
The CD4+ T cells in the bulk-cultured PBMCs of 
patient X-14 displayed the use of at least 16 different 
TCR-Vβ-families (Fig. 5a), of which one was considered 
dominant (Vβ5.1) and five were considered subdominant 
(Vβ2/3/8/14/21.3). The bulk-cultured PBMCs showed 
a broad response to all five overlapping XAGE-1b pep-
tides, the peptide mix and to XAGE-1b protein (Fig. 5b). 
A total of 10 XAGE-1b-specific CD4+ T cell clones were 
obtained of which eight were analyzed for TCR-Vβ usage. 
Staining for the dominant TCR-Vβ 5.1 was demonstrated 
for four clones, whereas the subdominant TCR-Vβ 21.3 
was expressed by one clone (Fig. 5c). The established 
clones showed XAGE-1b-specific proliferation when stim-
ulated with p1, p2, the peptide mix and XAGE-1b protein, 
indicating that CD4+ T cell clones isolated from this cul-
ture recognized their naturally processed cognate antigen. 
Flow cytometric analysis of intracellular Foxp3 expression 
by the isolated clones did not reveal the presence of this 
transcription factor (data not shown).
Taken together, we conclude that T cell reactivity to 
XAGE-1b involves polyclonal CD4+ and CD8+ T cell 
populations with the capacity to recognize the naturally 
processed antigen and reactive to peptide epitopes different 
from those recognized by the IgG antibodies.
Discussion
This is the first study on the immunogenicity of XAGE-1b 
in a Caucasian study cohort of 40 pulmonary adenocarci-
noma patients. We found XAGE-1b protein expression to 
be present in 43.6 % of cases, which is within the frequency 
range (33–53 %) reported for Asian patients [10, 11, 24]. 
XAGE-1b was expressed in both primary and metastatic 
tumor specimens. However, XAGE-1b-positive tumors do 
not show protein overexpression in all tumor samples nor 
in all fields covering an area that approximates the size 
of a bronchial biopsy. Hence, the frequency of XAGE-
1b-overexpressing tumors can be underestimated when 
only assessing a single section of the tumor and most likely 
when a biopsy is analyzed. Based on our findings, showing 
that sometimes only 2 out of 10 randomly analyzed tumor 
fields stain positive for XAGE-1b, its status is probably 
best assessed by the analysis of at least two sections of the 
primary tumor or five biopsies. Moreover, our study reveals 
for the first time the presence of XAGE-1b-specific T cells 
in the primary lung tumor and the tumor-draining lymph 
nodes from 2 out of 20 evaluated patients. The XAGE-
1b-reactive T cells displayed both a Th1 (IFNγ/TNFα) 
and Th2 (IL-5/IL-10) cytokine polarization. These results 
indicate that XAGE-1b-specific T cells can contribute to 
the anti-tumor response, but the low response rate among 
patients also implies that the spontaneous activation of T 
cells to XAGE-1b is limited.
In our cohort, we observed XAGE-1b-specific IgG 
antibodies in 3 of 40 patients (7.5 %). Two previous stud-
ies with Asian adenocarcinoma patients also assessed 
anti-XAGE-1b antibody frequency. The first study [11] 
found a XAGE-1b IgG frequency of 8.9 % in a simi-
lar (mainly stage I/II) patient group. The second study 
[13] found a higher frequency (19 %) of XAGE-1b IgG 
responses, but this was in stage IIIb/IV patients. Possibly, 
XAGE-1b-specific antibodies are more prevalent in patients 
with a more advanced tumor stage, as also observed for 
antibodies against p53, NY-ESO-1 and survivin [25].
The presence of XAGE-1b-specific IgG antibodies was 
accompanied by an antigen-specific T cell response in the 
peripheral blood of all three antibody-positive patients. In 
one patient (X-4), an ex vivo IFNγ response to XAGE-1b 
peptide mix was found by ELISPOT assay, whereas in two 
patients (X-4 and X-14), Th1 and Th2 cytokine responses 
were found after one round of in vitro stimulation of 
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PBMCs with XAGE-1b overlapping peptides. In-depth 
analysis revealed that the XAGE-1b-specific T cell popula-
tion comprised both CD4 and CD8 T cells producing both 
Th1 and Th2 cytokines. The T cells reacted mainly to the 
overlapping peptides p1 and p2. Recently, this N-termi-
nal part of XAGE-1b was shown to comprise a CD4+ T 
cell epitope (aa 18–31) and an overlapping CD8+ T cell 
epitope (aa 21–29) [13]. Our study confirms this part of 
XAGE-1b as a T cell epitope-containing domain. Interest-
ingly, while the T cell response was predominantly directed 
against sequences present in p1 and p2, the dominant B cell 
response was targeted to p5 of XAGE-1b within the small 
group of patients positive in this study.
In one patient (X-27, Supplementary Figure 6), an 
underlying XAGE-1b-specific T cell response was only 
detected after removal of a myeloid CD14+ population 
from the PBMC sample. Immature myeloid cell popula-
tions have been shown to inhibit T cell activation [26, 27], 
and their suppressive activity has been specifically reported 
for NSCLC [22, 23, 28]. Therefore, removal of the poten-
tially suppressive myeloid cell populations from the periph-
eral blood of adenocarcinoma patients before analysis of T 
cell responses might reveal a higher percentage of XAGE-
1b-specific T cell responders among Caucasian patients. In 
addition, based on the current success with co-inhibitory 
receptor blocking in patients with NSCLC [7], one could 
consider to test the response in assays where known co-
inhibitory receptors are blocked.
In conclusion, our study demonstrates that XAGE-1b 
acts as a genuine tumor antigen eliciting integrated sys-
temic and/or tumor-infiltrating antigen-specific humoral 
and cellular immune responses in Caucasian patients with 
pulmonary adenocarcinoma. As such, this tumor antigen 
forms an attractive target for active immunotherapy in lung 
cancer using XAGE-1b-based therapeutic vaccines. Based 
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Fig. 5  TCR-Vβ expression and XAGE-1b-specific proliferation of 
bulk-cultured PBMCs of patient X-14. a Sixteen different TCR-Vβ 
families were discovered in the bulk-cultured PBMCs of patient 
X-14. b XAGE-1b-specific proliferation (conducted in two separate 
assays) demonstrated a broad response to all 5 overlapping XAGE-
1b peptides, the peptide mix and to XAGE-1b protein. c In total, 10 
clones were isolated from the expanded PBMCs; XAGE-1b-specific 
proliferation and TCR-Vβ usage are shown for three clones with dif-
ferent patterns of antigen recognition (p1, p2, the peptide mix and 
XAGE-1b protein) and TCR-Vβ expression (Vβ 21.3 and 5.1)
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responses in non-vaccinated patients, it is not to be 
expected that the induction of such a response by XAGE-
1b vaccination will result in safety problems. Based on 
these results, we have recently started a phase 1 clinical 
trial with XAGE-1b synthetic long peptides.
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